IPO Boutique

Aeglea Therapeutics, Inc. IPO Advisory

Share this IPO Profile:

Smart Search
Company begins with...
Company contains...

For IPO Boutique's "scale of 1 to 5" BUY rating on Aeglea Therapeutics, Inc., and our comprehensive analysis, click "Buy Market Research".
Company
Symbol
Price Range
Issue Price
Open
Shares
Trade Date
Aeglea Therapeutics, Inc.AGLE -
NASDAQ
$16.00-$18.00 $10.00 $10.005 million4/7/2016
UBS Investment Bank, BMO Capital Markets, Wells Fargo Securities
Co-Manager(s):
Needham & Co.
Health Care
Filing(s):

Filed 2015-06-16
Underwriters Changed 2015-09-14
Underwriters added 2015-11-05
Terms Added 2016-03-28



Aeglea Therapeutics, Inc. Quote & Chart - Click for current quote - AGLE

About Aeglea Therapeutics, Inc. (adapted from Aeglea Therapeutics, Inc. prospectus):
They are a biopharmaceutical company committed to developing enzyme-based therapeutics in the field of amino acid metabolism that they believe will transform the lives of patients with inborn errors of metabolism and cancer.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.



IPO Boutique aggregates information on public companies and private companies, such as "AGLE" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.

Used our Comprehensive Single Promo Advisory and want more?
We also offer a monthly or annual subscription






© 2005 - 2024 IPO Boutique. All Rights Reserved